Equillium, Inc. (EQ) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Equillium, Inc. (EQ) closed at USD 1.30 on 2026-10-14, a change of -3.7 % over the past year, with a market capitalization of USD 83.7M.

Equillium, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Equillium, Inc. key figures

Previous close

USD 1.30 (2026-10-14)

1-year change

-3.7 %

Market cap

USD 83.7M

Enterprise value

USD 27.12M

P/E ratio (trailing)

-9.43

P/E ratio (forward)

-5.57

EPS (trailing)

-0.14

EPS (forward)

-0.24

PEG ratio

n/a

Price to book

1.49

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.51

Employees

14

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Equillium, Inc.

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Equillium, Inc. and compare it with other stocks.